JP2018188400A - Bedsore therapeutic agent - Google Patents
Bedsore therapeutic agent Download PDFInfo
- Publication number
- JP2018188400A JP2018188400A JP2017093759A JP2017093759A JP2018188400A JP 2018188400 A JP2018188400 A JP 2018188400A JP 2017093759 A JP2017093759 A JP 2017093759A JP 2017093759 A JP2017093759 A JP 2017093759A JP 2018188400 A JP2018188400 A JP 2018188400A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous solution
- calcium
- vitamin
- skin wound
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
Abstract
Description
本発明は、褥瘡治療剤及び褥瘡治療方法並びに皮膚創傷治療剤及び皮膚創傷治療方法に関するものである。 The present invention relates to a pressure ulcer treatment agent, a pressure ulcer treatment method, a skin wound treatment agent, and a skin wound treatment method.
褥瘡は、圧迫性壊疽の一つであり、主に身体の一部が長期間にわたって圧迫されることが主要因となり、湿潤や低栄養等による組織耐久性の低下によって発生する。 Pressure sores are one type of pressure gangrene, and are mainly caused by pressure on a part of the body over a long period of time, and are caused by a decrease in tissue durability due to moisture, malnutrition, or the like.
この褥瘡は、症状に応じてＩＡＥＴ（International Association for Enterstomal Therapy）で４つのステージに分類されており、ステージIからステージIVへと進行するにしたがって深達度（深さ）が大きくなり、治療に長期間を要している（たとえば、特許文献１参照。）。 This pressure ulcer is classified into four stages according to the IAET (International Association for Enterstomal Therapy) according to the symptoms, and the depth (depth) increases as it progresses from stage I to stage IV. It takes a long time (see, for example, Patent Document 1).
主に、長期間病床にある重症患者や高齢者は、皮膚表面組織や皮下組織が脆弱化しており、栄養状態が必ずしも十分ではないことがあり、褥瘡の発生リスクが高い。 Mainly, severely ill patients and elderly people who have been in the bed for a long time have weak skin surface tissues and subcutaneous tissues, and nutritional status may not always be sufficient, and the risk of developing pressure ulcers is high.
そのため、昨今の高齢化社会などを考えると、褥瘡の効果的な治療剤や治療方法の開発が望まれている。 Therefore, in view of the recent aging society, development of effective therapeutic agents and treatment methods for pressure ulcers is desired.
そこで、請求項１に係る本発明では、ビタミンＣ及びカルシウムの水溶液等（水溶液ないしローションやクリームや噴霧剤）を主成分とすることを特徴とする褥瘡治療剤を提供する。 Accordingly, the present invention according to claim 1 provides a pressure ulcer treatment agent characterized by comprising an aqueous solution of vitamin C and calcium (aqueous solution or lotion, cream or spray) as a main component.
また、請求項２に係る本発明では、ビタミンＣの水溶液等によって皮膚の基底層の細胞にコラーゲンとエラスチンの遺伝子を発現させ、転写してできたｍＲＮＡを翻訳させ、産生してくるエラスチンのカルシウム結合サイト３ヶ所にカルシウムを結合させると３本のpreコラーゲンをエラスチンで縄をなうようにして繊維ができ、断裂した繊維を修復し、褥瘡を治療することを特徴とする褥瘡治療方法を提供する。この事で、浮き上がって来つつ有る表皮を元に戻して真皮にくっつける事が出来る。穿刺等で開いた血管壁も修復することが出来る。 Further, in the present invention according to claim 2, elastin calcium is produced by expressing collagen and elastin genes in cells of the basal layer of the skin with an aqueous solution of vitamin C or the like, translating the mRNA produced by transcription, and producing the calcium. Providing a pressure ulcer treatment method characterized in that, when calcium is bound to three binding sites, fibers are formed by tying three pre-collagens together with elastin, repairing the broken fibers, and treating pressure ulcers To do. With this, it is possible to put the epidermis that is coming up and put it back to the dermis. A blood vessel wall opened by puncture or the like can also be repaired.
また、請求項３に係る本発明では、ビタミンＣ及びカルシウムの水溶液等を主成分とすることを特徴とする皮膚創傷治療剤を提供する。 Moreover, in this invention which concerns on Claim 3, the skin wound therapeutic agent characterized by mainly having the aqueous solution of vitamin C and calcium, etc. is provided.
また、請求項４に係る本発明では、ビタミンＣの水溶液等によって真皮を形成する細胞にコラーゲンやエラスチンの遺伝子を発現させ、カルシウムの水溶液等によって遺伝子発現したエラスチンのカルシウム結合サイトに二価のカルシウムイオンを結合させ、コラーゲンのカルシウム結合サイトにエラスチンを結合させて束ね、皮膚の創傷を治療することを特徴とする皮膚創傷治療方法を提供する。このような機序からして、動静脈注射後の弛緩開放も予防出来る。 In the present invention according to claim 4, collagen or elastin genes are expressed in cells that form the dermis with an aqueous solution of vitamin C or the like, and divalent calcium is present at the calcium binding site of elastin that is expressed by an aqueous solution of calcium or the like. There is provided a method for treating skin wounds, characterized by binding ions, binding elastin to a calcium binding site of collagen and bundling them to treat a skin wound. Such a mechanism can also prevent relaxation after arteriovenous injection.
そして、本発明では、以下に記載する効果を奏する。 And in this invention, there exists an effect described below.
すなわち、本発明では、褥瘡の発生によって分断された真皮内部のコラーゲンをビタミンＣの水溶液等によって遺伝子の発現を促進させることができ、分断されたコラーゲンを修復し、そのコラーゲンを束ねる為にエラスチンをカルシウムの水溶液等によって活性型に変化させることができ、エラスチンによってコラーゲンの線維を束ね、これにより、褥瘡を治療することができる。 That is, in the present invention, collagen expression in the dermis separated by the occurrence of pressure ulcer can be promoted in gene expression by an aqueous solution of vitamin C, etc., and elastin is used to repair the fragmented collagen and bind the collagen. It can be changed to an active form by an aqueous solution of calcium or the like, and collagen fibers are bundled by elastin, whereby pressure ulcer can be treated.
また、本発明では、褥瘡だけでなく皮膚の創傷についても前記同様に治療することができる。 In the present invention, not only pressure ulcers but also skin wounds can be treated in the same manner as described above.
以下に、本願発明に係る褥瘡治療剤又は褥瘡治療方法若しくは皮膚創傷治療剤又は皮膚創傷治療方法の具体的な構成について説明する。 Hereinafter, a specific configuration of the pressure ulcer treatment agent, pressure ulcer treatment method, skin wound treatment agent, or skin wound treatment method according to the present invention will be described.
褥瘡治療剤又は皮膚創傷治療剤は、ビタミンＣ及びカルシウムの水溶液等（水溶液ないしローションやクリームや噴霧剤）を主成分とする薬剤である。たとえば、生理食塩水５００ｍｌに水溶性のビタミンＣと水溶性のカルシウム（例：グルコン酸カルシウム水和物等）とを溶解させて治療液を生成し、その治療液を脱脂綿等に浸透させたものである。 A pressure ulcer treatment agent or a skin wound treatment agent is a medicine mainly composed of an aqueous solution of vitamin C and calcium (aqueous solution, lotion, cream or spray). For example, a treatment solution is produced by dissolving water-soluble vitamin C and water-soluble calcium (eg, calcium gluconate hydrate) in 500 ml of physiological saline, and the treatment solution is permeated into absorbent cotton or the like It is.
この褥瘡治療剤又は皮膚創傷治療剤は、ビタミンＣ及びカルシウムの水溶液等を主成分とすればよく、水溶性のビタミンＣや水溶性のカルシウムを溶解させたものが含まれていればよい。溶媒としては、代表的には身体に影響を及ぼさない生理食塩水が用いられるが、純水、アルコールなどでもよい。また、褥瘡治療剤又は皮膚創傷治療剤は、水溶性のビタミンＣや水溶性のカルシウムを溶解させた液体状の治療液でもよく、その治療液をゼリー状にしたものでもよく、脱脂綿等に浸漬させたものでもよく、さらに、水溶性のビタミンＣを溶解させた液体と水溶性のカルシウムを溶解させた液体とを混合させた治療液に限られず、それぞれの液体を別々に用いたものであってもよい。 The pressure ulcer treatment agent or skin wound treatment agent may be mainly composed of an aqueous solution of vitamin C and calcium, etc., and may contain water-soluble vitamin C or water-soluble calcium dissolved therein. As the solvent, physiological saline that does not affect the body is typically used, but pure water, alcohol, or the like may be used. The pressure ulcer treatment agent or skin wound treatment agent may be a liquid treatment solution in which water-soluble vitamin C or water-soluble calcium is dissolved, or may be a jelly-like treatment solution, which is immersed in absorbent cotton or the like. In addition, the liquid is not limited to a treatment liquid in which a liquid in which water-soluble vitamin C is dissolved and a liquid in which water-soluble calcium is dissolved, but each liquid is used separately. May be.
上記いずれかの構成の褥瘡治療剤又は皮膚創傷治療剤は、以下に説明するように使用することで褥瘡治療方法又は皮膚創傷治療方法に利用できる。 The pressure ulcer therapeutic agent or skin wound therapeutic agent having any one of the above structures can be used for a pressure ulcer treatment method or a skin wound therapeutic method by using it as described below.
まず、患部に上記いずれかの構成の褥瘡治療剤又は皮膚創傷治療剤を塗布する。たとえば、ビタミンＣ及びカルシウムを溶解させた治療液を脱脂綿に浸透させたものでは、患部の表面を脱脂綿で被覆する。また、ビタミンＣ及びカルシウムを溶解させた治療液では、患部の表面に直接治療液を塗布する。また、ビタミンＣとカルシウムとをそれぞれ溶解させた液体では、患部の表面にそれぞれの液体を同時に塗布してもよく、先に患部の表面にビタミンＣを溶解させた液体を塗布した後にカルシウムを塗布した液体を塗布してもよい。 First, a pressure ulcer treatment agent or a skin wound treatment agent having any one of the above-described structures is applied to the affected area. For example, in a case where a treatment liquid in which vitamin C and calcium are dissolved is permeated into absorbent cotton, the surface of the affected area is covered with absorbent cotton. In the case of a treatment solution in which vitamin C and calcium are dissolved, the treatment solution is applied directly to the surface of the affected area. Moreover, in the liquid which each dissolved vitamin C and calcium, you may apply | coat each liquid simultaneously on the surface of an affected part, and apply | coat calcium after apply | coating the liquid which dissolved vitamin C first on the surface of an affected part. The liquid may be applied.
皮膚の表皮よりも下層の真皮の内部においては、密なコラーゲンの線維の結合体の中に弾性線維としてのエラスチンが網状に分布している。しかし、褥瘡や皮膚創傷の場合、真皮の内部のコラーゲンの線維がダメージを受けて分断された状態となっている。 Within the dermis below the epidermis of the skin, elastin as elastic fibers is distributed in a network in dense collagen fiber conjugates. However, in the case of pressure sores and skin wounds, collagen fibers in the dermis are damaged and broken.
褥瘡や皮膚創傷の患部に上記いずれかの構成の褥瘡治療剤又は皮膚創傷治療剤を塗布すると、ビタミンＣの水溶液が皮膚の真皮の内部にまで浸透する。ビタミンＣは、真皮内部で分断されたコラーゲンとエラスチンに対して遺伝子の発現を促進させる。これにより、真皮内部で分断されたコラーゲンが修復されて線維状のコラーゲンとなる。 When the pressure ulcer treatment agent or skin wound treatment agent having any one of the above structures is applied to the affected area of pressure ulcer or skin wound, an aqueous solution of vitamin C penetrates into the dermis of the skin. Vitamin C promotes gene expression for collagen and elastin that are disrupted within the dermis. As a result, the collagen separated in the dermis is repaired to become fibrous collagen.
また、褥瘡や皮膚創傷の患部に上記いずれかの構成の褥瘡治療剤又は皮膚創傷治療剤を塗布すると、カルシウムの水溶液が皮膚の真皮の内部にまで浸透する。カルシウムは、真皮内部で修復された線維状のコラーゲンを結束するためのエラスチンに対して遺伝子の発現を促進させる。これにより、真皮内部で線維状のコラーゲンがエラスチンによって結束される。 Moreover, when the pressure ulcer treatment agent or skin wound treatment agent having any one of the above-described structures is applied to the affected area of pressure ulcer or skin wound, an aqueous solution of calcium penetrates into the dermis of the skin. Calcium promotes gene expression for elastin to bind fibrous collagen repaired inside the dermis. As a result, fibrous collagen is bound by elastin inside the dermis.
このようにして、皮膚の内部の組織が修復され、褥瘡や皮膚創傷が治癒する。 In this way, the tissue inside the skin is repaired and the pressure ulcer and skin wound are healed.
以上に説明したように、本発明に係る褥瘡治療剤又は皮膚創傷治療剤は、ビタミンＣ及びカルシウムの水溶液等を主成分とするものであり、ビタミンＣの水溶液等によって真皮内部のコラーゲンの遺伝子を発現させ、カルシウムの水溶液等によって遺伝子発現したコラーゲンのエラスチンの遺伝子を発現させることで、褥瘡や皮膚創傷を治療することができるものである。 As explained above, the pressure ulcer treatment agent or skin wound treatment agent according to the present invention is mainly composed of an aqueous solution of vitamin C and calcium, etc., and the collagen gene in the dermis is transferred by an aqueous solution of vitamin C or the like. It is possible to treat pressure ulcers and skin wounds by expressing the elastin gene of collagen that is expressed and gene-expressed with an aqueous solution of calcium or the like.
なお、本発明で言う皮膚創傷は、真皮内部のコラーゲン線維がダメージを受けた状態を指し、切り傷や刺し傷に限られず、注射痕なども含む概念である。 The skin wound referred to in the present invention refers to a state in which collagen fibers in the dermis are damaged, and is not limited to cuts and stabs, but is a concept including injection marks.
そこで、請求項１に係る本発明では、水溶性のビタミンＣ及びカルシウムを生理食塩水に溶解させた水溶液を患部を被覆する脱脂綿に浸透させたことを特徴とする褥瘡治療剤を提供する。
Therefore, the present invention according to claim 1 provides an anti- decubitus therapeutic agent characterized in that an aqueous solution in which water- soluble vitamin C and calcium are dissolved in physiological saline is permeated into absorbent cotton covering the affected area .
また、請求項２に係る本発明では、水溶性のビタミンＣを生理食塩水に溶解させた水溶液と、前記ビタミンＣの水溶液を患部に塗布した後に塗布するための水溶性のカルシウムを生理食塩水に溶解させた水溶液と、からなることを特徴とする褥瘡治療剤を提供する。
Further, in the present invention according to claim 2, an aqueous solution in which water-soluble vitamin C is dissolved in physiological saline, and water-soluble calcium for application after the aqueous solution of vitamin C is applied to the affected area are added to the physiological saline. An anti-decubitus therapeutic agent characterized by comprising an aqueous solution dissolved in
また、請求項３に係る本発明では、水溶性のビタミンＣ及びカルシウムを生理食塩水に溶解させた水溶液をゼリー状にしたことを特徴とする褥瘡治療剤を提供する。
The present invention according to claim 3 provides an anti- decubitus therapeutic agent characterized in that an aqueous solution in which water- soluble vitamin C and calcium are dissolved in physiological saline is made into a jelly form .
また、請求項４に係る本発明では、水溶性のビタミンＣを生理食塩水に溶解させた水溶液をゼリー状にしたものと、前記ビタミンＣの水溶液を患部に塗布した後に塗布するための水溶性のカルシウムを生理食塩水に溶解させた水溶液をゼリー状にしたものと、からなることを特徴とする褥瘡治療剤を提供する。 Further, in the present invention according to claim 4, an aqueous solution in which water-soluble vitamin C is dissolved in physiological saline is made into a jelly form, and water-soluble for application after applying the aqueous solution of vitamin C to the affected area. A pressure ulcer treatment agent characterized by comprising: an aqueous solution prepared by dissolving a calcium salt in physiological saline into a jelly form.
Claims (4)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017093759A JP2018188400A (en) | 2017-05-10 | 2017-05-10 | Bedsore therapeutic agent |
| TW107115557A TW201900161A (en) | 2017-05-10 | 2018-05-08 | Bedsore therapeutic agent and bedsore treatment method, and skin wound therapeutic agent and skin wound treatment method |
| PCT/JP2018/017908 WO2018207812A1 (en) | 2017-05-10 | 2018-05-09 | Bedsore therapeutic agent and bedsore treatment method, and skin wound therapeutic agent and skin wound treatment method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017093759A JP2018188400A (en) | 2017-05-10 | 2017-05-10 | Bedsore therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2018188400A true JP2018188400A (en) | 2018-11-29 |
Family
ID=64105284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017093759A Pending JP2018188400A (en) | 2017-05-10 | 2017-05-10 | Bedsore therapeutic agent |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2018188400A (en) |
| TW (1) | TW201900161A (en) |
| WO (1) | WO2018207812A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500368A (en) * | 2002-08-21 | 2006-01-05 | アクファーマ インコーポレイテッド | Skin condition treatment composition and method |
| JP2011219411A (en) * | 2010-04-08 | 2011-11-04 | Hiroshima Kasei Ltd | Liquid for treating bedsore for external use and apparatus for treating bedsore |
| CN103830267A (en) * | 2012-11-22 | 2014-06-04 | 孟华 | Compound external anti-ulcer tablet |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1245220C (en) * | 2003-04-09 | 2006-03-15 | 江苏阳生生物工程有限公司 | New dressing matorial for promoting quick repair of surface of dermal wound |
| US9387194B2 (en) * | 2012-01-18 | 2016-07-12 | Human Matrix Sciences, Llc | Sodium ascorbate stimulation of elastogenesis |
-
2017
- 2017-05-10 JP JP2017093759A patent/JP2018188400A/en active Pending
-
2018
- 2018-05-08 TW TW107115557A patent/TW201900161A/en unknown
- 2018-05-09 WO PCT/JP2018/017908 patent/WO2018207812A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006500368A (en) * | 2002-08-21 | 2006-01-05 | アクファーマ インコーポレイテッド | Skin condition treatment composition and method |
| JP2011219411A (en) * | 2010-04-08 | 2011-11-04 | Hiroshima Kasei Ltd | Liquid for treating bedsore for external use and apparatus for treating bedsore |
| CN103830267A (en) * | 2012-11-22 | 2014-06-04 | 孟华 | Compound external anti-ulcer tablet |
Non-Patent Citations (1)
| Title |
|---|
| 小池他: "アスコルビン酸軟膏，蛋白同化ステロイド軟膏の肉芽組織に対する影響", JOURNAL OF JAPANESE SOCIETY OF HOSPITAL PHARMACISTS, vol. 20, no. 1, JPN6018024072, 1984, pages 17 - 20, ISSN: 0003960619 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201900161A (en) | 2019-01-01 |
| WO2018207812A1 (en) | 2018-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stanley et al. | Effects of negative pressure wound therapy on healing of free full‐thickness skin grafts in dogs | |
| CN206214465U (en) | Skin or surface of a wound combine dressing and its external member | |
| Li et al. | Complications of negative pressure wound therapy: a mini review | |
| ATE551976T1 (en) | METHOD FOR PRODUCING A SOLID BANDAGE FOR THE TREATMENT OF INJURED TISSUE | |
| CN105056285B (en) | It is a kind of can adhesion organization crack growth factor combine dressing and preparation method thereof | |
| El‐Amawy et al. | Saline in dermatology: a literature review | |
| Bevis et al. | Venous ulcer review | |
| GB2474851A (en) | Wound dressing comprising anti-microbial honey encapsulated within biocompatible and biodegradable fibre, and the fibre's production | |
| WO2006034293A3 (en) | Wound care dressing and method using same | |
| RU2423118C1 (en) | Method of treating trophic ulcers | |
| JP2018188400A (en) | Bedsore therapeutic agent | |
| Holder et al. | Effects of hyperbaric oxygen on full-thickness meshed sheet skin grafts applied to fresh and granulating wounds in horses | |
| RU2633060C2 (en) | Peeling compositions containing trichloroacetic acid (tca) and phenol to reduce burning caused by peeling with tca | |
| Petkar et al. | Vacuum closure as a skin-graft dressing: a comparison against conventional dressing | |
| Gilmore et al. | Treatment of ulcers on legs by pinch grafts and a supportive dressing of polyurethane | |
| Onesti et al. | Reconstruction after skin cancer excision through a dermal induction template: our experience | |
| Bukovcan et al. | Clinical experience with the use of negative pressure wound therapy combined with a silver-impregnated dressing in mixed wounds: a retrospective study of 50 cases | |
| Liden et al. | Hypochlorous acid: Its multiple uses for wound care | |
| RU2498776C1 (en) | Method of treating infected wounds of anterior abdominal wall | |
| Walczak et al. | Management of large chronic venous leg ulcers with negative pressure wound therapy | |
| Fraccalvieri et al. | The combination of a hypertonic saline dressing and negative pressure wound therapy for quick and bloodless debridement of difficult lesions in complicated patients | |
| RU2547386C1 (en) | Regenerative bioplasty technique for investing tissue defects | |
| Ahmad et al. | Vacuum assisted closure therapy: role in modern plastic surgery | |
| RU2608431C1 (en) | Method of closing defects of low-intensity wounds of lower extremities in diabetic foot syndrome | |
| IT9021606A1 (en) | COMPOSITION FOR THERAPEUTIC AND / OR COSMETIC USE FOR THE TREATMENT OF CIRCULATORY DISORDERS AND FOR AESTHETIC MEDICINE TREATMENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180529 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180529 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180831 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181219 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20181228 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191126 |